Skip to main content
Detailed chapter

Neuroendocrine Tumors (NET)

Neuroendocrine tumors vary from indolent to aggressive NEC — grade and differentiation change how treatment is planned.

NETs secrete or silently grow along the gut and pancreas with a wide biological spectrum. Grade (Ki-67/mitoses) and differentiation separate relatively indolent NETs from high-grade neuroendocrine carcinomas that need different chemotherapy mindsets. Functional syndromes (carcinoid, insulinoma, etc.) add hormone-control tasks to tumor control tasks. These tumors follow sarcoma or neuroendocrine rules, not generic adenocarcinoma pathways. Bring your top three questions to the visit.

NET · educational illustration

Educational schematic. Some structures may be simplified or emphasized for clarity; not an exact anatomical depiction.

© Cengiz Dibekoğlu — illustrative; not for unauthorized use

Figure summary

This educational figure shows: NET.

Who may be a candidate?

  • International patients preparing a structured second-opinion visit
  • Patients comparing observation, medical care, and procedural options

Possible advantages

  • Supports informed consent with alternatives and recovery themes
  • Highlights red flags that should trigger urgent contact

Limits & realistic expectations

  • Cannot replace examination, imaging, or pathology
  • Local protocols and tumor-board decisions may refine timing
  • Outcomes vary with anatomy, stage, and comorbidity

Step-by-step overview

  1. 1

    Clarify the clinical question

    What diagnosis is being confirmed and what decision follows?

  2. 2

    Choose first-line tests

    Start with the test that answers the leading question safely.

  3. 3

    Stage if needed

    Add imaging or endoscopy when results would change management.

  4. 4

    Name limitations

    No test replaces exam; false reassurance is a risk.

  5. 5

    Link to next step

    Diagnosis should point to observation, medical care, or procedure.

Key points

  • Important

    Key note inside

    This page is for education. It is not medical advice and does not replace a visit with your physician.

Frequently asked questions

  • What is the difference between NET and NEC?

    Grade and differentiation separate relatively indolent NETs from aggressive neuroendocrine carcinomas with different treatments.

  • Do all NETs produce hormones?

    No. Functional and non-functional tumors are managed differently.

  • Why is Ki-67 important?

    It helps grade the tumor and shapes therapy intensity.

  • Is surgery always first?

    Not for every stage; systemic and liver-directed options appear in selected algorithms.

This page is for education. It is not medical advice and does not replace a visit with your physician.

Medical editor: Assoc. Prof. Cengiz Dibekoğlu, MD · Last medically reviewed: August 2026 · English patient-education chapter.